GlassScriptPhysician profile
Nizam Razack
NPI 1447237045
$2,115.79
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $157 · 2021: $232 · 2022: $792 · 2024: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $427 · Food and Beverage: $30.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $427.35 |
| Food and Beverage | $30.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integrity Implants INC. | $676.81 | 2022 | |
| Arthrex, INC. | $427.35 | 2024 | |
| Nanovis LLC | $232.00 | 2020-2021 | |
| Bard Access Systems, INC. | $140.35 | 2019 | |
| Medtronic USA, INC. | $132.86 | 2019 | |
| Microvention, INC. | $123.93 | 2019 | |
| Insightec,INC | $115.54 | 2022 | |
| Centinel Spine, LLC | $106.88 | 2020 | |
| Orthofix Medical, INC. | $79.81 | 2019 | |
| Stryker Corporation | $49.65 | 2021 | |
| Nevro Corp. | $30.61 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$399,989.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nizam Razack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.